Showing 249 results

Filters Content type: News, Editors' picks, About HIV Topic: Injectable & long-acting PrEP

The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.

Injectable & long-acting PrEP

The Launch of Lenacapavir in Zambia

Editor's pick
AVAC
25 March 2026
Injectable & long-acting PrEP

CAB-LA: The prevention jab that never had its moment, and what it leaves behind as LEN arrives

Editor's pick
Bhekisisa
16 March 2026
Injectable & long-acting PrEP

South Africa launches bid to enable local production of long-acting HIV prevention drug, lenacapavir

Editor's pick
Unitaid
7 March 2026
Injectable & long-acting PrEP

Islatravir PrEP didn’t protect against M184V mutation in macaque study

Editor's pick
i-Base
1 March 2026
Injectable & long-acting PrEP

New research: High prevention efficacy and “breakthrough infections” on lenacapavir for PrEP

Editor's pick
San Francisco AIDS Foundation
1 March 2026
Injectable & long-acting PrEP

Long-Acting Cabotegravir Shows High PrEP Effectiveness in Black Women

Editor's pick
Infectious Disease Advisor
27 February 2026
Injectable & long-acting PrEP

Zimbabwe’s Lenacapavir rollout: The gap between hope and truth

Editor's pick
Be In The Know
27 February 2026
Injectable & long-acting PrEP

Zimbabwe Rolls Out New HIV Prevention Drug Lenacapavir

Editor's pick
Medscape (requires free registration)
23 February 2026
Injectable & long-acting PrEP

Cabotegravir injections for PrEP

About HIV
February 2026
Access to healthcare

Civil Society Demands Access Strategy for Merck’s Promising Long-Acting HIV Prevention Pill Covering all Low- and Middle-Income Countries

Editor's pick
Health GAP (Global Access Project)
12 February 2026
Access to healthcare

Twice-Yearly Lenacapavir Injection for HIV Prevention in Nigeria: The Real Test Is Access

Editor's pick
Nigeria Health Watch
6 February 2026
PrEP policies & guidelines

Where is HIV prevention drug lenacapavir in ‘America First’ health deals?

Editor's pick
Devex (requires free registration)
6 February 2026
PrEP policies & guidelines

US: ‘Transformative’ HIV PrEP shot slowly overcomes cost hurdles

Editor's pick
The Hill
1 February 2026
Access to healthcare

New US research: Out of thousands, only 42 people started long-acting injectable PrEP

Editor's pick
San Francisco AIDS Foundation
26 January 2026
Access to healthcare

US: PrEP Users Applaud CVS and Gilead Agreement on Yeztugo

Editor's pick
PrEP4All
15 January 2026
Injectable & long-acting HIV treatment

Lenacapavir Resistance May Impair HIV Fitness

Editor's pick
POZ
12 January 2026
Transgender people

Lenacapavir PrEP Does Not Interfere With Hormone Therapy for Trans People

Editor's pick
POZ
22 December 2025
PrEP policies & guidelines

MHRA approves lenacapavir for the prevention of sexually transmitted HIV-1 infection

Editor's pick
Medicines and Healthcare products Regulatory Agency (MHRA)
22 December 2025
PrEP policies & guidelines

South Africa wants to make its own six-monthly HIV prevention jabs by 2027. But there’s a hitch

Editor's pick
Bhekisisa
8 December 2025
PrEP programmes & uptake

Huge disparities in PrEP uptake across Europe – injectable PrEP largely inaccessible

News
17 November 2025
Drug interactions & pharmacokinetics

No Negative Impact for Individuals Taking Lenacapavir and Gender-Affirming Hormone Therapy

Editor's pick
Contagion Live
3 November 2025
Injectable & long-acting PrEP

Gilead's long-acting PrEP Yeztugo takes off while cell therapy declines continue to haunt sales

Editor's pick
FiercePharma
3 November 2025
PrEP policies & guidelines

Breakthrough HIV prevention jab given green light in South Africa

Editor's pick
Spotlight
27 October 2025
Injectable & long-acting PrEP

South African firms lose out on lenacapavir production

Editor's pick
Juta MedicalBrief
23 October 2025